Cost-effectiveness analysis of fumarate furosemide compared with omeprazole in treatment of gastroesophageal reflux
Hu Li-xiu
Lin Cheng-jiang
Xu Lei
Lyu Liang-yan
Abstract：Objective To investigate the cost-effectiveness of volnoxan fumarate and omeprazole in the treatment of gas-troesophageal reflux(GERD)to provide a reference for the rational selection of drugs in the clinic.Methods One hundred and thirty-seven patients with GERD admitted to Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from February 2021 to January 2024 were selected and randomly divided into two groups:69 patients in the vonorasan group were treated with vonorasan fumarate tablets,and 68 patients in the omeprazole group were treated with omeprazole enteric-coated tablets.The treatment effects,time to clinical symptom relief,gastrointestinal hormone levels,incidence of adverse effects and cost-effective-ness ratios were compared between the two groups.Results The treatment effectiveness rate of 94.20%(65/69)in the vonorasan group was higher than 82.35%(56/68)in the omeprazole group(χ2=4.712,P<0.05).The time for clinical symptoms such as reflux,heartburn,abdominal pain,belching and other clinical symptoms to be relieved was shorter in the voronasan group((10.23±2.54)d,(11.57±2.39)d,(12.82±2.48)d,(13.14±2.72)d,respectively)than that in the omeprazole group((13.51±3.16)d,(14.23±2.85)d,(15.56±3.07)d,(17.35±3.56)d)(t=6.701,5.923,5.750,7.785,all P<0.05).After treatment,vasoactive intestinal peptide(VIP)level((42.49±6.22)pg·mL-1)was decreased,and gastrin(MTL)and gastrin(GAS)levels((243.36±16.43)pg·mL-1,(55.83±7.84)pg·mL-1,respectively)were elevated in the voronasan group,which were higher than those in the omeprazole group((47.52±6.90)pg·mL-1,(232.93±17.15)pg·mL-1,(50.79±7.51)pg·mL-1)(t=4.483,3.635,3.842,all P<0.05).In terms of adverse reactions,the overall inci-dence of 13.04%(9/69)in the vonorasan group was not significantly different from that of 16.81%(11/68)in the omeprazole group(χ2=0.270,P>0.05).In the cost-effectiveness analysis,the cost-effectiveness ratios of patients with GERD classified as LA grade A,B,and C treated with vonoprazan were all lower than those treated with omeprazole(U=45.315,32.697,69.624;all P<0.05).Among GERD patients with effective,marked and complete responses to treatment,the cost-effectiveness ratios of those treated with vono-prazan were also lower than those treated with omeprazole(U=52.314,39.687,59.487;all P<0.05).Conclusion The treatment of patients with GERD using volnoxan fumarate is superior to that using omeprazole in terms of therapeutic efficacy,time to clinical symptom relief and gastrointestinal hormone levels,and is more cost-effective.
Keywords：Vonoprazan fumarateOmeprazoleGastrooesophageal reflux diseaseEfficacyCost-effectiveness ratio
Publication Date：2025-02-24
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 153-157 )